Roflumilast: Antiallergy/antiasthmatic treatment of COPD phosphodiesterase 4 inhibitor

Drugs of the Future

Volumn 25, Issue 12, 2000, Pages 1261-1264

  Sorbera, L A ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; ADENOSINE A2 RECEPTOR ANTAGONIST; AWD 12 343; BAY 19 8004; CGH 2466; CILOMILAST; CL 1018; CL 1044; D 4418; IPL 4088; L 826141; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROTEIN C; PROTEIN KINASE INHIBITOR; PUMAFENTIRINE; PUMAFENTRINE; RECOMBINANT PROTEIN; ROFLUMILAST; SURFACTANT ASSOCIATED PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ASTHMA; CHEMICAL ANALYSIS; CHEMICAL REACTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT;

EID: 0034481372     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.12.604045     Document Type: Article

References (16)

1. Characteristics of asthma care provided by hospitals in a large metropolitan area - Results from the Chicago Asthma Surveillance Initiative
2. A possible mediator role for endothelin-1 in respiratory disease
3. Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future?
4. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition
5. Locally produced tumor necrosis factor-α mediates interleukin-2-induced lung injury
6. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4
7. Current and potential new therapies for chronic obstructive pulmonary disease
8. Additive effects of phosphodiesterase-4 inhibition on effects of rSP-C surfactant
9. Safety-related performance is not impaired by the new PDE4-inhibitor roflumilast
10. Four-week treatment with the new PDE4 inhibitor roflumilast in patients with exercise-induced asthma: Safety, efficacy and inhibition of TNF-α ex vivo
11. Safety and efficacy of the new PDE4 inhibitor roflumilast, administered to patients with exercise-induced asthma over 4 weeks